Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,600 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study.
Fokkens W, Trigg A, Lee SE, Chan RH, Diamant Z, Hopkins C, Howarth P, Lund V, Mayer B, Sousa AR, Yancey S, Tabberer M; SYNAPSE study group. Fokkens W, et al. Among authors: mayer b. J Patient Rep Outcomes. 2023 Jan 20;7(1):4. doi: 10.1186/s41687-023-00543-5. J Patient Rep Outcomes. 2023. PMID: 36662344 Free PMC article. Clinical Trial.
Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, Smith SG, Martin N, Mayer B, Yancey SW, Sousa AR, Chan R, Hopkins C; SYNAPSE study investigators. Han JK, et al. Among authors: mayer b. Lancet Respir Med. 2021 Oct;9(10):1141-1153. doi: 10.1016/S2213-2600(21)00097-7. Epub 2021 Apr 16. Lancet Respir Med. 2021. PMID: 33872587
Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count.
Bachert C, Sousa AR, Han JK, Schlosser RJ, Sowerby LJ, Hopkins C, Maspero JF, Smith SG, Kante O, Karidi-Andrioti DE, Mayer B, Chan RH, Yancey SW, Chaker AM. Bachert C, et al. Among authors: mayer b. J Allergy Clin Immunol. 2022 May;149(5):1711-1721.e6. doi: 10.1016/j.jaci.2021.10.040. Epub 2022 Jan 7. J Allergy Clin Immunol. 2022. PMID: 35007624 Free article. Clinical Trial.
Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps.
Borish L, Cohen NA, Chupp G, Hopkins C, Wagenmann M, Sousa AR, Smith SG, Silver J, Yang S, Mayer B, Yancey SW, Chan RH, Fokkens W. Borish L, et al. Among authors: mayer b. Ann Allergy Asthma Immunol. 2022 Aug;129(2):160-168. doi: 10.1016/j.anai.2022.04.004. Epub 2022 Apr 8. Ann Allergy Asthma Immunol. 2022. PMID: 35398492 Free article. Review.
Evaluating treatment response to mepolizumab in patients with severe CRSwNP.
Hopkins C, Han JK, Lund VJ, Bachert C, Fokkens WJ, Diamant Z, Mullol J, Sousa AR, Smith SG, Yang S, Mayer B, Yancey SW, Chan RH, Lee SE. Hopkins C, et al. Among authors: mayer b. Rhinology. 2023 Apr 1;61(2):108-117. doi: 10.4193/Rhin22.200. Rhinology. 2023. PMID: 36716382 Clinical Trial.
Mepolizumab Reduces Systemic Corticosteroid Use in Chronic Rhinosinusitis With Nasal Polyps.
Chupp G, Alobid I, Lugogo NL, Kariyawasam HH, Bourdin A, Chaker AM, Smith SG, Sousa AR, Mayer B, Chan RH, Matucci A. Chupp G, et al. Among authors: mayer b. J Allergy Clin Immunol Pract. 2023 Nov;11(11):3504-3512.e2. doi: 10.1016/j.jaip.2023.08.015. Epub 2023 Aug 14. J Allergy Clin Immunol Pract. 2023. PMID: 37586475 Free article. Clinical Trial.
1,600 results